Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14,128 | 1 | 84.2% |
| Honoraria | $1,500 | 3 | 8.9% |
| Grant | $700.00 | 2 | 4.2% |
| Consulting Fee | $386.67 | 1 | 2.3% |
| Food and Beverage | $65.05 | 2 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $14,128 | 1 | $0 (2017) |
| Athenex Pharmaceutical Division, LLC | $1,522 | 4 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $700.00 | 2 | $0 (2024) |
| Becton, Dickinson and Company | $386.67 | 1 | $0 (2017) |
| GlaxoSmithKline, LLC. | $43.33 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $700.00 | 2 | AstraZeneca Pharmaceuticals LP ($700.00) |
| 2020 | $1,000 | 2 | Athenex Pharmaceutical Division, LLC ($1,000) |
| 2019 | $521.72 | 2 | Athenex Pharmaceutical Division, LLC ($521.72) |
| 2017 | $14,558 | 3 | PFIZER INC. ($14,128) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/03/2024 | AstraZeneca Pharmaceuticals LP | — | Grant | Cash or cash equivalent | $350.00 | General |
| 02/28/2024 | AstraZeneca Pharmaceuticals LP | — | Grant | Cash or cash equivalent | $350.00 | General |
| 06/05/2020 | Athenex Pharmaceutical Division, LLC | Oral Paclitaxel (Drug), Encequidar | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: Metastatic Breast Cancer | ||||||
| 02/03/2020 | Athenex Pharmaceutical Division, LLC | Oral Paclitaxel (Drug), Encequidar | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: Metastatic Breast Cancer | ||||||
| 07/11/2019 | Athenex Pharmaceutical Division, LLC | Oral Paclitaxel (Drug), Encequidar | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: Metastatic Breast Cancer | ||||||
| 07/03/2019 | Athenex Pharmaceutical Division, LLC | Oral Paclitaxel (Drug), Encequidar | Food and Beverage | In-kind items and services | $21.72 | General |
| Category: Metastatic Breast Cancer | ||||||
| 12/31/2017 | PFIZER INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $14,128.00 | General |
| 10/24/2017 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $43.33 | General |
| 08/17/2017 | Becton, Dickinson and Company | — | Consulting Fee | Cash or cash equivalent | $386.67 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 169 | 333 | $166,990 | $32,788 |
| 2022 | 5 | 201 | 368 | $176,817 | $35,806 |
| 2021 | 4 | 195 | 344 | $146,587 | $33,245 |
| 2020 | 7 | 245 | 386 | $151,754 | $32,108 |
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 58 | 146 | $88,546 | $16,833 | 19.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 91 | 114 | $46,132 | $8,600 | 18.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 20 | 73 | $32,312 | $7,355 | 22.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 64 | 146 | $87,364 | $17,709 | 20.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 93 | 114 | $45,403 | $8,853 | 19.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 20 | 83 | $33,781 | $7,264 | 21.5% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 13 | 13 | $5,499 | $1,128 | 20.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 11 | 12 | $4,770 | $851.72 | 17.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 64 | 148 | $75,082 | $17,822 | 23.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 79 | 105 | $36,343 | $8,179 | 22.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 20 | 55 | $23,195 | $4,916 | 21.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 32 | 36 | $11,967 | $2,328 | 19.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 30 | 101 | $41,915 | $9,356 | 22.3% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 50 | 97 | $47,196 | $8,483 | 18.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 65 | 77 | $24,402 | $4,370 | 17.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 21 | 22 | $17,776 | $3,789 | 21.3% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 44 | 52 | $9,984 | $3,456 | 34.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 19 | 20 | $8,640 | $1,922 | 22.2% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 16 | 17 | $1,841 | $731.60 | 39.7% |
About Dr. Jeffrey Peppercorn, MD
Dr. Jeffrey Peppercorn, MD is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1053471599.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Peppercorn, MD has received a total of $16,780 in payments from pharmaceutical and medical device companies, with $700.00 received in 2024. These payments were reported across 9 transactions from 5 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($14,128).
As a Medicare-enrolled provider, Peppercorn has provided services to 810 Medicare beneficiaries, totaling 1,431 services with total Medicare billing of $133,946. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 12/12/2006
- Last Updated 01/23/2015
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1053471599
Products in Payments
- Oral Paclitaxel (Drug) $1,522
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795